Resistance to AR signaling inhibitors (ARSi) in a subset of metastatic castration-resistant prostate cancers (mCRPC) occurs with emergence of AR-negative Neuroendocrine Prostate Cancer (NEPC), coupled with mutations/deletions in PTEN, TP53, RB1, and overexpression of DNMTs, EZH2, and/or SOX2.